BioSyent Releases Q1 2017 Results
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 05/25/17 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include:
"Q1 2017 marked BioSyent''s 27th consecutive profitable quarter" remarked Rene Goehrum, President and CEO of BioSyent. "While we maintained a healthy net profit margin, Q1 2017 growth was somewhat constrained, in part, by the lower inventory carrying levels of our Canadian pharmaceutical wholesaler customers which limited our sales of FeraMAX® during the quarter. As we continue to advance launch stage products in our Canadian hospital business, such as CYSVIEW® and the Aguettant System® line of pre-filled syringes, and with the bulk of our 2017 international pharmaceutical business coming in the last nine months of 2017, we are confident in the capacity of our product portfolio to deliver the growth that we expect in 2017. We are also encouraged by a recently announced national survey of physicians and pharmacists which recognized our FeraMAX® brand as the #1 recommended iron supplement brand in Canada for the second consecutive year."
The CEO''s presentation on the Q1 2017 Results is available at the following link:
The Company''s Interim Unaudited Condensed Consolidated Financial Statements and Management''s Discussion and Analysis for the three months ended March 31, 2017 and 2016 will be posted on on May 25, 2017.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit .
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.
As of the date of this press release, the Company has 14,472,453 shares issued and outstanding.
Contacts:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.05.2017 - 06:00 Uhr
Sprache: Deutsch
News-ID 1505815
Anzahl Zeichen: 3396
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 344 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioSyent Releases Q1 2017 Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioSyent Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
